ABOUT

CUREBIO

THERAPEUTICS


Curebio Therapeutics is engaged in the discovery and devel

opment of potential first-in-class medicines based  on newly discovered pathway effected by ARSs (Aminoacyl tRNA Synth

etases)


·Translating novel biology ARS into first-in-class therapies

·MOA of our pipelines was published at eminent academic        

   journals


Curebio Therapeutics is engaged in the discovery and devel

opment of potential first-in-class medicines based  on newly discovered pathway effected by ARSs (Aminoacyl tRNA Synth

etases)

CEO

Min chul Park, Ph.D


Dr. Park has worked for 10 years in the field of target discovery, assay development and drug candidate optimization in the pharmaceutical industry. 


He has expertise in molecular and cellular biology from basic to applied. 


He obtained PhD in pharmacy department from Seoul National University with a thesis focusing on the role and mechanism of secreted glycyl-tRNA synthetase, the origin protein of CBT1424, 

in cancer microenvironment. 


Based on secreted glycyl-tRNA synthetase, he has developed anti-cancer peptide, CBT1424 in CurebioTX Co. Ltd..


BOD

Seo Yong Cho, Ph.D


Dr. Cho has 20 years of technology commercialization with extensive experience in technology licensing from academia to industry. 


Prior to Curebio, Dr. Cho was responsible for the commercialization of Seoul National University (SNU)’s technologies.


The commercialization includes either licensing technologies/patents concerned or starting up a new company by researchers. 


Before joining SNU, he found his own company, Cerectron, Ltd. producing nano materials for pharmaceutical applications and had been worked as CEO for about 10 years. 


He received his Ph.D in Material Science from SNU.

He is a certified licensing professional and a board member of Licensing Executive Society of Korea.

Scientific Advisory Board

Prof. Roger Kornberg


Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006. 


Collectively, Dr. Kornberg’s research has revolutionized modern genetics, molecular biology and the understanding of pathogenesis of various cancer malignancies. 


Among Dr. Kornberg’s many awards and prizes was the Alfred P. Sloan, Jr., Prize from the  General Motors Cancer Research Foundation, and the Robert J. and Claire Pasarow Foundation    Medical Research Award in Cancer Research.

OUR SCIENCE

ARSs

BIOLOGY

ARSs are essential enzymes for protein synthesis with evolutionarily conserved enzymatic mechanisms. 

(ARSs ligate amino acids to their corresponding tRNAs.) 


ARS were originally thought to only play a role in protein syn

thesis but recent genomic and proteomic advances have unveiled hidden biological functions of ARSs beyond their catalytic roles. 


ARSs have potential for new therapeutic targets and agents through multiple avenues, including direct targeting of the catalytic sites and developing novel biologics from the secreted ARS protein or their peptides. 


[Nature reviews drug discovery 18, 629-650, 2019]

① Targeting catalytic sites

② Targeting PPls

③ Therapeutic potential of secreted ARSs

OUR SCIENCE

ARSs [Aminoacyl tRNA Synthetases]

BIOLOGY

ARSs are essential enzymes for protein synthesis with evolutionarily conserved enzymatic mechanisms. (ARSs ligate amino acids to their corresponding tRNAs.) 


ARS were originally thought to only play a role in protein synthesis but recent genomic and proteomic advances have unveiled hidden biological functions of ARSs beyond their catalytic roles. 


ARSs have potential for new therapeutic targets and agents through multiple avenues, including direct targeting of the catalytic sites and developing novel biologics from the secreted ARS protein or their peptides. 


[Nature reviews drug discovery 18, 629-650, 2019]

①  Targeting catalytic sites

② Targeting PPls

③ Therapeutic potential of secreted ARSs

Linkage map of ARSs with various human 

diseases

The diverse connections of ARSs with various human diseas

es make them attractive as targets for the development of therapeutics. Two of the synthetase-GRS and AIMP1 have been studied in detail for their alternative functions in cell signaling pathways at CurebioTX.


PNAS 32 : 11043-11049 (2008)


PUBLICATIONS

REVIEW

CBT 1424

CBT 2001/2004/2005

CBT 1424

CBT 1424

PUBLICATIONS

REVIEW

CBT1424

CBT 2001 / 2004 / 2005

CBC 2002 / 2003

CBD 0901

INTELLECTUAL

PROPERTY

PATENTS

Curebio Therapeutics has built intellectual

property portfolio covering GRS and AIMP1 peptides


PATENTS

INTELLECTUAL

PROPERTY

Curebio Therapeutics has built intellectual

property portfolio covering GRS and AIMP1 peptides

R&D

PIPELINE

Currently CurebioTX  has three defined development projects, all based on our research on human proteins. Our two drug candidates, NeoPep GT and NeoPep A1H are small peptides. Glycyl-tRNA synthetase (GRS)-derived peptides (NeoPep GT) are a series of anti-tumorigenic peptides derived from the natural immune-surveillance agent, GRS. ARS-interacting multifunctional protein 1 (AIMP1)-derived peptides (NeoPep A1H) comprise a hair growth peptide derived from the natural anti-aging agent, AIMP1. The profile of each drug candidate is described in short in the following diagram.

ProgramIndicationResearchPreclinicalPhase1Phase2Phase3
CBT1424


Renal Cell Carcinoma*
Ovarian Cancer
Liver/Lung Cancer
CBT2004Alopecia
CBT2005Wound care
CBD0901Sepsis(Diagnostic)**Clinical trial for medical device
CBT2001Anti-aging
Commercially available for cosmetics
CBC2002Wrinkle care
Licence-out (INCI code: sh-oligopeptide 84)
CBC2003Whitening

Licence-out (INCI code: sh-oligopeptide 91 SP)

* In partnership with Neo TX

** In partnership with JW Bioscience



CUREBIOTX 

NEWS

게시물이 없습니다.

CUREBIO THERAPEUTICS

We are a passionate and dynamic group of scientists, engineers, designers and business folk. 

Our goal: empower people to live healthier, longer.


Contact Details

Room 1201, AceGwanggyoTower2, Yeongtong-gu, Suwon, Gyeonggi, Korea (ZIP 16229)


E-mail: contact@curebiotx.com

CUREBIO THERAPEUTICS


We are a passionate and dynamic group of scientists, engineers, designers and business folk. 

Our goal: empower people to live healthier, longer.

Contact Details


Room 1201, AceGwanggyoTower2, 

Yeongtong-gu, Suwon, Gyeonggi, Korea 

(ZIP 16229)

E-mail


contact@curebiotx.com